Arecor Therapeutics PLC (AIM:AREC), the biopharmaceutical group, has signed an additional formulation agreement with one of its top five global pharmaceutical partners, marking the eighth new technology partnership since the company's IPO in June 2021.
The collaboration will utilise Arecor's proprietary formulation technology platform, Arestat, to develop improved, stable, high concentration, liquid formulations of its proprietary product.
The partner company will fund the initial development work and have the option to acquire the rights to the new proprietary formulations and associated intellectual property.
Arecor chief executive Sarah Howell said the collaboration highlights the adaptability of Arecor's technology, and further cements the company's reputation as a go-to partner for complex formulation expertise in the industry.